Richard S. Geary - Dec 14, 2023 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP, Chief Development Officer
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Richard S. Geary
Stock symbol
IONS
Transactions as of
Dec 14, 2023
Transactions value $
-$23,817
Form type
4
Date filed
12/18/2023, 04:55 PM
Previous filing
Sep 5, 2023
Next filing
Dec 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $311K +6.57K +9.01% $47.34 79.5K Dec 14, 2023 Direct
transaction IONS Common Stock Sale -$323K -6.57K -8.26% $49.21 73K Dec 14, 2023 Direct F1
transaction IONS Common Stock Options Exercise $191K +4.04K +5.54% $47.34 77K Dec 14, 2023 Direct
transaction IONS Common Stock Sale -$203K -4.04K -5.25% $50.19 73K Dec 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -6.57K -30.96% $0.00 14.7K Dec 14, 2023 Common Stock 6.57K $47.34 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -4.04K -27.58% $0.00 10.6K Dec 14, 2023 Common Stock 4.04K $47.34 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $49.75 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.